Company intelligence / Profile preview

GeneCraft

Cheongju-si, Chungcheongbuk-do, South Koreatutorials.gencraft.com ↗

Ownership: Private
Development stage: Other

Overview

GeneCraft is a pre-clinical-stage biotech developing first-in-class gene therapies for pan-KRAS mutated cancers, with its lead program focused on NSCLC. The company leverages a proprietary AAV platform to selectively target and kill KRAS-mutant tumor cells. No clinical results have been published yet as all programs are preclinical.

Therapeutic areas: Oncology
Modalities: Gene therapy (AAV-based)
Industry: Biotech

Drug pipeline

1 asset

RX001

Beyond the preview

Go deeper on GeneCraft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneCraft.

Explore the full profile